-
2
-
-
34848907420
-
Overview of epidemiologic studies of diabetic retinopathy
-
Klein BE: Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol 2007; 14:179-183.
-
(2007)
Ophthalmic Epidemiol
, vol.14
, pp. 179-183
-
-
Klein, B.E.1
-
5
-
-
34547869213
-
Pharmacothera-pies for diabetic retinopathy: Present and future
-
Schwartz SG, Flynn HW Jr: Pharmacothera-pies for diabetic retinopathy: present and future. Exp Diabetes Res 2007;2007:52487.
-
(2007)
Exp Diabetes Res 2007
, pp. 52487
-
-
Schwartz, S.G.1
Flynn Jr, H.W.2
-
6
-
-
0032797880
-
Drusen in age-related macular degeneration: Pathogenesis, natural course, and laser pho-tocoagulation-induced regression
-
Abdelsalam A, Del Priore L, Zarbin MA: Drusen in age-related macular degeneration: pathogenesis, natural course, and laser pho-tocoagulation-induced regression. Surv Ophthalmol 1999;44:1-29.
-
(1999)
Surv Ophthalmol
, vol.44
, pp. 1-29
-
-
Abdelsalam, A.1
Del Priore, L.2
Zarbin, M.A.3
-
7
-
-
0032448463
-
Age-related macular degeneration: Review of pathogenesis
-
Zarbin MA: Age-related macular degeneration: review of pathogenesis. Eur J Ophthalmol 1998;8:199-206.
-
(1998)
Eur J Ophthalmol
, vol.8
, pp. 199-206
-
-
Zarbin, M.A.1
-
8
-
-
44349085868
-
Retinal precursors and the development of geographic atrophy in age-related macular degeneration
-
Klein ML, Ferris FL 3rd, Armstrong J, et al: Retinal precursors and the development of geographic atrophy in age-related macular degeneration. Ophthalmology 2008; 115: 1026-1031.
-
(2008)
Ophthalmology
, vol.115
, pp. 1026-1031
-
-
Klein, M.L.1
Ferris 3rd, F.L.2
Armstrong, J.3
-
10
-
-
0023224438
-
Pathophysiology of age-related macular degeneration
-
Young RW: Pathophysiology of age-related macular degeneration. Surv Ophthalmol 1987;31:291-306.
-
(1987)
Surv Ophthalmol
, vol.31
, pp. 291-306
-
-
Young, R.W.1
-
11
-
-
33846475583
-
Thermal laser treatment in AMD: Therapeutic and prophylactic
-
Cukras C, Fine SL: Thermal laser treatment in AMD: therapeutic and prophylactic. Int Ophthalmol Clin 2007;47:75-93.
-
(2007)
Int Ophthalmol Clin
, vol.47
, pp. 75-93
-
-
Cukras, C.1
Fine, S.L.2
-
13
-
-
33749451356
-
Ra-nibizumab versus verteporfin for neovascular age-related macular degeneration
-
Brown DM, Kaiser PK, Michels M, et al: Ra-nibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444.
-
(2006)
N Engl J Med
, vol.355
, pp. 1432-1444
-
-
Brown, D.M.1
Kaiser, P.K.2
Michels, M.3
-
14
-
-
33749445317
-
Ra-nibizumab for neovascular age-related macular degeneration
-
Rosenfeld PJ, Brown DM, Heier JS, et al: Ra-nibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355: 1419-1431.
-
(2006)
N Engl J Med
, vol.355
, pp. 1419-1431
-
-
Rosenfeld, P.J.1
Brown, D.M.2
Heier, J.S.3
-
15
-
-
34548721616
-
Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: Applying clinical trial results to the treatment of everyday patients
-
Brown DM, Regillo CD: Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients. Am J Ophthalmol 2007; 144:627-637.
-
(2007)
Am J Ophthalmol
, vol.144
, pp. 627-637
-
-
Brown, D.M.1
Regillo, C.D.2
-
16
-
-
77957339328
-
Ocular implants for drugdelivery
-
Wnek GE, Bowlin GL eds, New York, Dekker
-
Lee SS, Yuan P, Robinson MR: Ocular implants for drugdelivery; in Wnek GE, Bowlin GL (eds): Encyclopedia of Biomaterials and Biomedical Engineering. New York, Dekker, 2004.
-
(2004)
Encyclopedia of Biomaterials and Biomedical Engineering
-
-
Lee, S.S.1
Yuan, P.2
Robinson, M.R.3
-
18
-
-
41149178633
-
Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascular-ization and retinal edema
-
Doukas J, Mahesh S, Umeda N, et al: Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascular-ization and retinal edema. J Cell Physiol 2008;216:29-37.
-
(2008)
J Cell Physiol
, vol.216
, pp. 29-37
-
-
Doukas, J.1
Mahesh, S.2
Umeda, N.3
-
19
-
-
45749143528
-
Retinal vascular permeability suppression by topical application of a novel VEGFR2/Src kinase inhibitor in mice and rabbits
-
Scheppke L, Aguilar E, Gariano RF, et al: Retinal vascular permeability suppression by topical application of a novel VEGFR2/Src kinase inhibitor in mice and rabbits. J Clin Invest 2008; 118:2337-2346.
-
(2008)
J Clin Invest
, vol.118
, pp. 2337-2346
-
-
Scheppke, L.1
Aguilar, E.2
Gariano, R.F.3
-
20
-
-
50449090755
-
Targeting intraocular neovascu-larization and edema - one drop at a time
-
Aiello LP: Targeting intraocular neovascu-larization and edema - one drop at a time. N Engl J Med 2008;359:967-969.
-
(2008)
N Engl J Med
, vol.359
, pp. 967-969
-
-
Aiello, L.P.1
-
21
-
-
28444440585
-
Recent progress in ocular drug delivery for posterior segment disease: Emphasis on transscleral iontophoresis
-
Myles ME, Neumann DM, Hill JM: Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis. Adv Drug Deliv Rev 2005;57: 2063-2079.
-
(2005)
Adv Drug Deliv Rev
, vol.57
, pp. 2063-2079
-
-
Myles, M.E.1
Neumann, D.M.2
Hill, J.M.3
-
22
-
-
33751268869
-
Intraocular implants for extended drug delivery: Therapeutic applications
-
Bourges JL, Bloquel C, Thomas A, et al: Intraocular implants for extended drug delivery: therapeutic applications. Adv Drug Deliv Rev 2006;58:1182-1202.
-
(2006)
Adv Drug Deliv Rev
, vol.58
, pp. 1182-1202
-
-
Bourges, J.L.1
Bloquel, C.2
Thomas, A.3
-
23
-
-
33751172532
-
Ocular delivery of nucleic acids: Antisense oligonucleotides, apta-mers and siRNA
-
Fattal E, Bochot A: Ocular delivery of nucleic acids: antisense oligonucleotides, apta-mers and siRNA. Adv Drug Deliv Rev 2006; 58:1203-1223.
-
(2006)
Adv Drug Deliv Rev
, vol.58
, pp. 1203-1223
-
-
Fattal, E.1
Bochot, A.2
-
25
-
-
34249787025
-
Ocular drugdelivery: Nanomedicine applications
-
Vandervoort J, Ludwig A: Ocular drugdelivery: nanomedicine applications. Nanomed 2007;2:11-21.
-
(2007)
Nanomed
, vol.2
, pp. 11-21
-
-
Vandervoort, J.1
Ludwig, A.2
-
26
-
-
34250685723
-
Ocular drug delivery: Molecules, cells, and genes
-
Liu X, Brandt CR, Rasmussen CA, Kaufman PL: Ocular drug delivery: molecules, cells, and genes. Can J Ophthalmol 2007;42:447-454.
-
(2007)
Can J Ophthalmol
, vol.42
, pp. 447-454
-
-
Liu, X.1
Brandt, C.R.2
Rasmussen, C.A.3
Kaufman, P.L.4
-
27
-
-
35048821557
-
Transport barriers in transscleral drug delivery for retinal diseases
-
Kim SH, Lutz RJ, Wang NS, Robinson MR: Transport barriers in transscleral drug delivery for retinal diseases. Ophthalmic Res 2007;39:244-254.
-
(2007)
Ophthalmic Res
, vol.39
, pp. 244-254
-
-
Kim, S.H.1
Lutz, R.J.2
Wang, N.S.3
Robinson, M.R.4
-
28
-
-
31344468895
-
A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone ace-tonide
-
Robinson MR, Lee SS, Kim H, et al: A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone ace-tonide. Exp Eye Res 2006;82:479-487.
-
(2006)
Exp Eye Res
, vol.82
, pp. 479-487
-
-
Robinson, M.R.1
Lee, S.S.2
Kim, H.3
-
29
-
-
33750600023
-
Delivery from episcleral exo-plants
-
Pontes de Carvalho RA, Krausse ML, Murphree AL, Schmitt EE, Campochiaro PA, Maumenee IH: Delivery from episcleral exo-plants. Invest Ophthalmol Vis Sci 2006;47: 4532-4539.
-
(2006)
Invest Ophthalmol Vis Sci
, vol.47
, pp. 4532-4539
-
-
Pontes de Carvalho, R.A.1
Krausse, M.L.2
Murphree, A.L.3
Schmitt, E.E.4
Campochiaro, P.A.5
Maumenee, I.H.6
-
30
-
-
0020660753
-
Physiology of the choroidal vascular bed
-
Bill A, Sperber G, Ujiie K: Physiology of the choroidal vascular bed. Int Ophthalmol 1983;6:101-107.
-
(1983)
Int Ophthalmol
, vol.6
, pp. 101-107
-
-
Bill, A.1
Sperber, G.2
Ujiie, K.3
-
31
-
-
0016907184
-
Observations on the corrosion costs of the choriocapillaries (author's transl)
-
Araki M: Observations on the corrosion costs of the choriocapillaries (author's transl). Nippon Ganka Gakkai Zasshi 1976; 80:315-326.
-
(1976)
Nippon Ganka Gakkai Zasshi
, vol.80
, pp. 315-326
-
-
Araki, M.1
-
32
-
-
0000510983
-
The drainage of albumin from the uvea
-
Bill A: The drainage of albumin from the uvea. Exp Eye Res 1964; 75:179-187.
-
(1964)
Exp Eye Res
, vol.75
, pp. 179-187
-
-
Bill, A.1
-
33
-
-
3242885512
-
Controlled drug release from an ocular implant: An evaluation using dynamic three-dimensional magnetic resonance imaging
-
Kim H, Robinson MR, Lizak MJ, et al: Controlled drug release from an ocular implant: an evaluation using dynamic three-dimensional magnetic resonance imaging. Invest Ophthalmol Vis Sci 2004;45:2722-2731.
-
(2004)
Invest Ophthalmol Vis Sci
, vol.45
, pp. 2722-2731
-
-
Kim, H.1
Robinson, M.R.2
Lizak, M.J.3
-
34
-
-
10644248274
-
Trans-Tenon retrobulbar triamcinolone infusion for chronic macular edema in central and branch retinal vein occlusion
-
Wakabayashi T, Okada AA, Morimura Y, et al: Trans-Tenon retrobulbar triamcinolone infusion for chronic macular edema in central and branch retinal vein occlusion. Retina 2004;24:964-967.
-
(2004)
Retina
, vol.24
, pp. 964-967
-
-
Wakabayashi, T.1
Okada, A.A.2
Morimura, Y.3
-
35
-
-
3042666103
-
Trans-Tenon's retrobulbar triamcinolone infusion for diffuse diabetic macular edema
-
Ohguro N, Okada AA, Tano Y: Trans-Tenon's retrobulbar triamcinolone infusion for diffuse diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 2004;242:444-445.
-
(2004)
Graefes Arch Clin Exp Ophthalmol
, vol.242
, pp. 444-445
-
-
Ohguro, N.1
Okada, A.A.2
Tano, Y.3
-
36
-
-
32944465175
-
Intravit-real injection versus sub-Tenon's infusion of triamcinolone acetonide for refractory diabetic macular edema: A randomized clinical trial
-
Bonini-Filho MA, Jorge R, Barbosa JC, Calucci D, Cardillo JA, Costa RA: Intravit-real injection versus sub-Tenon's infusion of triamcinolone acetonide for refractory diabetic macular edema: a randomized clinical trial. Invest Ophthalmol Vis Sci 2005;46: 3845-3849.
-
(2005)
Invest Ophthalmol Vis Sci
, vol.46
, pp. 3845-3849
-
-
Bonini-Filho, M.A.1
Jorge, R.2
Barbosa, J.C.3
Calucci, D.4
Cardillo, J.A.5
Costa, R.A.6
-
37
-
-
0037336290
-
Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a cor-ticosteroid capable of inhibiting VEGF expression
-
Kompella UB, Bandi N, Ayalasomayajula SP: Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a cor-ticosteroid capable of inhibiting VEGF expression. Invest Ophthalmol Vis Sci 2003;44: 1192-1201.
-
(2003)
Invest Ophthalmol Vis Sci
, vol.44
, pp. 1192-1201
-
-
Kompella, U.B.1
Bandi, N.2
Ayalasomayajula, S.P.3
-
38
-
-
6344284095
-
Retinal delivery of celecoxib is several-fold higher following subconjunctival administration compared to systemic administration
-
Ayalasomayajula SP, Kompella UB: Retinal delivery of celecoxib is several-fold higher following subconjunctival administration compared to systemic administration. Pharm Res 2004;21:1797-1804.
-
(2004)
Pharm Res
, vol.21
, pp. 1797-1804
-
-
Ayalasomayajula, S.P.1
Kompella, U.B.2
-
39
-
-
15744404419
-
Subcon-junctivally administered celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model
-
Ayalasomayajula SP, Kompella UB: Subcon-junctivally administered celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model. Eur J Pharmacol 2005; 511:191-198.
-
(2005)
Eur J Pharmacol
, vol.511
, pp. 191-198
-
-
Ayalasomayajula, S.P.1
Kompella, U.B.2
-
40
-
-
0033843428
-
A poly(ortho ester) designed for combined ocular delivery of dexamethasone sodium phosphate and 5-fluorouracil: Subconjunctival tolerance and in vitro release
-
Zignani M, Einmahl S, Baeyens V, et al: A poly(ortho ester) designed for combined ocular delivery of dexamethasone sodium phosphate and 5-fluorouracil: subconjunctival tolerance and in vitro release. Eur J Pharm Biopharm 2000;50:251-255.
-
(2000)
Eur J Pharm Biopharm
, vol.50
, pp. 251-255
-
-
Zignani, M.1
Einmahl, S.2
Baeyens, V.3
-
41
-
-
0037726627
-
-
Gilbert JA, Simpson AE, Rudnick DE, Geroski DH, Aaberg TM Jr, Edelhauser HF: Trans-scleral permeability and intraocular concentrations of cisplatin from a collagen matrix. J Control Release 2003;89:409-417
-
Gilbert JA, Simpson AE, Rudnick DE, Geroski DH, Aaberg TM Jr, Edelhauser HF: Trans-scleral permeability and intraocular concentrations of cisplatin from a collagen matrix. J Control Release 2003;89:409-417.
-
-
-
-
42
-
-
0029769636
-
In vitro and in vivo evaluation in rabbits of a controlled release 5-fluorouracil subconjunctival implant based on poly(D,L-lactide-co-glycolide)
-
Wang G, Tucker IG, Roberts MS, Hirst LW: In vitro and in vivo evaluation in rabbits of a controlled release 5-fluorouracil subconjunctival implant based on poly(D,L-lactide-co-glycolide). Pharm Res 1996; 13:1059-1064.
-
(1996)
Pharm Res
, vol.13
, pp. 1059-1064
-
-
Wang, G.1
Tucker, I.G.2
Roberts, M.S.3
Hirst, L.W.4
-
43
-
-
0037809363
-
Intraocular tissue distribution of betamethasone after intrascleral administration using a non-biodegradable sustained drug delivery device
-
Okabe K, Kimura H, Okabe J, Kato A, Kunou N, Ogura Y: Intraocular tissue distribution of betamethasone after intrascleral administration using a non-biodegradable sustained drug delivery device. Invest Ophthalmol Vis Sci 2003;44:2702-2707.
-
(2003)
Invest Ophthalmol Vis Sci
, vol.44
, pp. 2702-2707
-
-
Okabe, K.1
Kimura, H.2
Okabe, J.3
Kato, A.4
Kunou, N.5
Ogura, Y.6
-
44
-
-
0037308517
-
Biodegradable intrascleral implant for sustained intraocular delivery of betamethasone phosphate
-
Okabe J, Kimura H, Kunou N, Okabe K, Kato A, Ogura Y: Biodegradable intrascleral implant for sustained intraocular delivery of betamethasone phosphate. Invest Ophthalmol Vis Sci 2003;44:740-744.
-
(2003)
Invest Ophthalmol Vis Sci
, vol.44
, pp. 740-744
-
-
Okabe, J.1
Kimura, H.2
Kunou, N.3
Okabe, K.4
Kato, A.5
Ogura, Y.6
-
45
-
-
0347358065
-
Feasibility of drug delivery to the posterior pole of the rabbit eye with an episcleral implant
-
Kato A, Kimura H, Okabe K, Okabe J, Kunou N, Ogura Y: Feasibility of drug delivery to the posterior pole of the rabbit eye with an episcleral implant. Invest Ophthalmol Vis Sci 2004;45:238-244.
-
(2004)
Invest Ophthalmol Vis Sci
, vol.45
, pp. 238-244
-
-
Kato, A.1
Kimura, H.2
Okabe, K.3
Okabe, J.4
Kunou, N.5
Ogura, Y.6
-
46
-
-
0034114629
-
Transscleral delivery of bioactive protein to the choroid and retina
-
Ambati J, Gragoudas ES, Miller JW, et al: Transscleral delivery of bioactive protein to the choroid and retina. Invest Ophthalmol Vis Sci 2000;41:1186-1191.
-
(2000)
Invest Ophthalmol Vis Sci
, vol.41
, pp. 1186-1191
-
-
Ambati, J.1
Gragoudas, E.S.2
Miller, J.W.3
-
47
-
-
13944251659
-
Effect of benzalkonium chloride on transscleral drug delivery
-
Okabe K, Kimura H, Okabe J, et al: Effect of benzalkonium chloride on transscleral drug delivery. Invest Ophthalmol Vis Sci 2005;46: 703-708.
-
(2005)
Invest Ophthalmol Vis Sci
, vol.46
, pp. 703-708
-
-
Okabe, K.1
Kimura, H.2
Okabe, J.3
-
48
-
-
0037299842
-
Anecortave acetate as monotherapy for the treatment of subfoveal lesions in patients with exudative age-related macular degeneration (AMD): Interim (month 6) analysis of clinical safety and efficacy
-
D'Amico DJ, Goldberg MF, Hudson H, et al: Anecortave acetate as monotherapy for the treatment of subfoveal lesions in patients with exudative age-related macular degeneration (AMD): interim (month 6) analysis of clinical safety and efficacy. Retina 2003; 23:14-23.
-
(2003)
Retina
, vol.23
, pp. 14-23
-
-
D'Amico, D.J.1
Goldberg, M.F.2
Hudson, H.3
-
49
-
-
0344442766
-
Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: Twelvemonth clinical outcomes
-
discussion 2384-2385
-
D'Amico DJ, Goldberg MF, Hudson H, et al: Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelvemonth clinical outcomes. Ophthalmology 2003;110:2372-2383; discussion 2384-2385.
-
(2003)
Ophthalmology
, vol.110
, pp. 2372-2383
-
-
D'Amico, D.J.1
Goldberg, M.F.2
Hudson, H.3
-
50
-
-
24944566042
-
Comparison of intravitreal versus posterior sub-Tenon's capsule injection of triamcinolone acetonide for diffuse diabetic macular edema
-
Cardillo JA, Melo LA Jr, Costa RA, et al: Comparison of intravitreal versus posterior sub-Tenon's capsule injection of triamcinolone acetonide for diffuse diabetic macular edema. Ophthalmology 2005;112:1557-1563.
-
(2005)
Ophthalmology
, vol.112
, pp. 1557-1563
-
-
Cardillo, J.A.1
Melo Jr, L.A.2
Costa, R.A.3
-
51
-
-
1042301272
-
Drug delivery to the posterior segment of the eye. III: The effect of parallel elimination pathway on the vitreous drug level after subconjunctival injection
-
Lee TW, Robinson JR: Drug delivery to the posterior segment of the eye. III: the effect of parallel elimination pathway on the vitreous drug level after subconjunctival injection. J Ocul Pharmacol Ther 2004;20:55-64.
-
(2004)
J Ocul Pharmacol Ther
, vol.20
, pp. 55-64
-
-
Lee, T.W.1
Robinson, J.R.2
-
52
-
-
33745655043
-
A novel bioerodible deep scleral lamellar cy-closporine implant for uveitis
-
Gilger BC, Salmon JH, Wilkie DA, et al: A novel bioerodible deep scleral lamellar cy-closporine implant for uveitis. Invest Ophthalmol Vis Sci 2006;47:2596-2605.
-
(2006)
Invest Ophthalmol Vis Sci
, vol.47
, pp. 2596-2605
-
-
Gilger, B.C.1
Salmon, J.H.2
Wilkie, D.A.3
-
53
-
-
33750086968
-
Cannula-tion of the suprachoroidal space: A novel drug delivery methodology to the posterior segment
-
Olsen TW, Feng X, Wabner K, et al: Cannula-tion of the suprachoroidal space: a novel drug delivery methodology to the posterior segment. Am J Ophthalmol 2006; 142:777-787.
-
(2006)
Am J Ophthalmol
, vol.142
, pp. 777-787
-
-
Olsen, T.W.1
Feng, X.2
Wabner, K.3
-
54
-
-
67349252651
-
Drug delivery to the suprachoroidal space shows promise
-
March/April
-
Olsen TW: Drug delivery to the suprachoroidal space shows promise. Retina Today 2007; March/April:36-39.
-
(2007)
Retina Today
, pp. 36-39
-
-
Olsen, T.W.1
-
55
-
-
3042763334
-
Ocular pharmacoki-netics of fluocinolone acetonide after Re-tisert intravitreal implantation in rabbits over a 1-year period
-
Driot JY, Novack GD, Rittenhouse KD, Milazzo C, Pearson PA: Ocular pharmacoki-netics of fluocinolone acetonide after Re-tisert intravitreal implantation in rabbits over a 1-year period. J Ocul Pharmacol Ther 2004;20:269-275.
-
(2004)
J Ocul Pharmacol Ther
, vol.20
, pp. 269-275
-
-
Driot, J.Y.1
Novack, G.D.2
Rittenhouse, K.D.3
Milazzo, C.4
Pearson, P.A.5
-
56
-
-
67349277307
-
Dexamethasone posterior segment drug delivery system: Pharmacokinetics in vitrec-tomized and non-vitrectomized eyes
-
Indian Wells
-
Welty D, Kuppermann BD, Chang-Lin JE, et al: Dexamethasone posterior segment drug delivery system: pharmacokinetics in vitrec-tomized and non-vitrectomized eyes. 25th Annual Meet Am Soc Retina Specialists, Indian Wells, 2007.
-
(2007)
25th Annual Meet Am Soc Retina Specialists
-
-
Welty, D.1
Kuppermann, B.D.2
Chang-Lin, J.E.3
-
57
-
-
0141499061
-
Noninfectious en-dophthalmitis associated with intravitreal triamcinolone injection
-
Roth DB, Chieh J, Spirn MJ, Green SN, Yarian DL, Chaudhry NA: Noninfectious en-dophthalmitis associated with intravitreal triamcinolone injection. Arch Ophthalmol 2003;121:1279-1282.
-
(2003)
Arch Ophthalmol
, vol.121
, pp. 1279-1282
-
-
Roth, D.B.1
Chieh, J.2
Spirn, M.J.3
Green, S.N.4
Yarian, D.L.5
Chaudhry, N.A.6
-
58
-
-
16344389598
-
Complications of intravitreal injection of triamcinolone acetonide
-
Ozkiris A, Erkilic K: Complications of intravitreal injection of triamcinolone acetonide. Can J Ophthalmol 2005;40:63-68.
-
(2005)
Can J Ophthalmol
, vol.40
, pp. 63-68
-
-
Ozkiris, A.1
Erkilic, K.2
-
59
-
-
33947529092
-
Intravitreal triamcinolone acetonide for diabetic retinopathy
-
Jonas JB: Intravitreal triamcinolone acetonide for diabetic retinopathy. Dev Ophthalmol 2007;39:96-110.
-
(2007)
Dev Ophthalmol
, vol.39
, pp. 96-110
-
-
Jonas, J.B.1
-
60
-
-
34548355065
-
The risk of endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trials
-
Bhavsar AR, Ip MS, Glassman AR: The risk of endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trials. Am J Ophthalmol 2007; 144:454-456.
-
(2007)
Am J Ophthalmol
, vol.144
, pp. 454-456
-
-
Bhavsar, A.R.1
Ip, M.S.2
Glassman, A.R.3
-
62
-
-
0022347471
-
Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study
-
Early Treatment Diabetic Retinopathy Study research group
-
Early Treatment Diabetic Retinopathy Study research group: Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985; 103:1796-1806.
-
(1985)
Arch Ophthalmol
, vol.103
, pp. 1796-1806
-
-
-
63
-
-
0021874413
-
Effects of intravitreal administration of steroids on experimental subretinal neovascularization in the subhuman primate
-
Ishibashi T, Miki K, Sorgente N, Patterson R, Ryan SJ: Effects of intravitreal administration of steroids on experimental subretinal neovascularization in the subhuman primate. Arch Ophthalmol 1985; 103:708-711.
-
(1985)
Arch Ophthalmol
, vol.103
, pp. 708-711
-
-
Ishibashi, T.1
Miki, K.2
Sorgente, N.3
Patterson, R.4
Ryan, S.J.5
-
66
-
-
0034886327
-
Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema
-
Jonas JB, Sofker A: Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol 2001; 132:425-427.
-
(2001)
Am J Ophthalmol
, vol.132
, pp. 425-427
-
-
Jonas, J.B.1
Sofker, A.2
-
67
-
-
0033400347
-
The pathogenesis of edema in diabetic maculopathy
-
Antcliff RJ, Marshall J: The pathogenesis of edema in diabetic maculopathy. Semin Ophthalmol 1999; 14:223-232.
-
(1999)
Semin Ophthalmol
, vol.14
, pp. 223-232
-
-
Antcliff, R.J.1
Marshall, J.2
-
68
-
-
33750597534
-
Diabetic retinopathy: Seeing beyond glucose-induced microvascular disease
-
Antonetti DA, Barber AJ, Bronson SK, et al: Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. Diabetes 2006;55:2401-2411.
-
(2006)
Diabetes
, vol.55
, pp. 2401-2411
-
-
Antonetti, D.A.1
Barber, A.J.2
Bronson, S.K.3
-
69
-
-
0036240895
-
Intravitreal triamcinolone for refractory diabetic macular edema
-
Martidis A, Duker JS, Greenberg PB, et al: Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002; 109:920-927.
-
(2002)
Ophthalmology
, vol.109
, pp. 920-927
-
-
Martidis, A.1
Duker, J.S.2
Greenberg, P.B.3
-
70
-
-
0842267262
-
Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: Preliminary results of a prospective controlled trial
-
discussion 224-225
-
Massin P, Audren F, Haouchine B, et al: Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology 2004; 111:218-224; discussion 224-225.
-
(2004)
Ophthalmology
, vol.111
, pp. 218-224
-
-
Massin, P.1
Audren, F.2
Haouchine, B.3
-
71
-
-
33646448054
-
Intravitreal toxicity of the kenalog vehicle (benzyl alcohol) in rabbits
-
Morrison VL, Koh HJ, Cheng L, Bessho K, Davidson MC, Freeman WR: Intravitreal toxicity of the kenalog vehicle (benzyl alcohol) in rabbits. Retina 2006;26:339-344.
-
(2006)
Retina
, vol.26
, pp. 339-344
-
-
Morrison, V.L.1
Koh, H.J.2
Cheng, L.3
Bessho, K.4
Davidson, M.C.5
Freeman, W.R.6
-
72
-
-
21244445737
-
Intravitreal preservative-free triamcinolone acetonide for the treatment of macular oedema
-
Bakri SJ, Shah A, Falk NS, Beer PM: Intravitreal preservative-free triamcinolone acetonide for the treatment of macular oedema. Eye 2005;19:686-688.
-
(2005)
Eye
, vol.19
, pp. 686-688
-
-
Bakri, S.J.1
Shah, A.2
Falk, N.S.3
Beer, P.M.4
-
73
-
-
7444245438
-
Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: Three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial
-
Sutter FK, Simpson JM, Gillies MC: Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology 2004; 111:2044-2049.
-
(2004)
Ophthalmology
, vol.111
, pp. 2044-2049
-
-
Sutter, F.K.1
Simpson, J.M.2
Gillies, M.C.3
-
74
-
-
33747623255
-
Intravitreal triamcinolone for refractory diabetic macular edema: Two-year results of a double-masked, placebo-controlled, randomized clinical trial
-
Gillies MC, Sutter FK, Simpson JM, Larsson J, Ali H, Zhu M: Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 2006;113:1533-1538.
-
(2006)
Ophthalmology
, vol.113
, pp. 1533-1538
-
-
Gillies, M.C.1
Sutter, F.K.2
Simpson, J.M.3
Larsson, J.4
Ali, H.5
Zhu, M.6
-
75
-
-
33749602030
-
One-year safety and efficacy of intravitreal triamcinolone acetonide for the management of macular edema secondary to central retinal vein occlusion
-
Gregori NZ, Rosenfeld PJ, Puliafito CA, et al: One-year safety and efficacy of intravitreal triamcinolone acetonide for the management of macular edema secondary to central retinal vein occlusion. Retina 2006;26:889-895.
-
(2006)
Retina
, vol.26
, pp. 889-895
-
-
Gregori, N.Z.1
Rosenfeld, P.J.2
Puliafito, C.A.3
-
76
-
-
34347223601
-
The effect of intravitreal triamcinolone on intraocular pressure
-
Kramar M, Vu L, Whitson JT, He YG: The effect of intravitreal triamcinolone on intraocular pressure. Curr Med Res Opin 2007; 23:1253-1258.
-
(2007)
Curr Med Res Opin
, vol.23
, pp. 1253-1258
-
-
Kramar, M.1
Vu, L.2
Whitson, J.T.3
He, Y.G.4
-
77
-
-
34548509483
-
Two-year results of intravitreal triamcinolone acetonide injection for the treatment of diabetic macular edema
-
Batioglu F, Ozmert E, Parmak N, Celik S: Two-year results of intravitreal triamcinolone acetonide injection for the treatment of diabetic macular edema. Int Ophthalmol 2007;27:299-306.
-
(2007)
Int Ophthalmol
, vol.27
, pp. 299-306
-
-
Batioglu, F.1
Ozmert, E.2
Parmak, N.3
Celik, S.4
-
78
-
-
38049141027
-
Short-term complications of intravitreal injection of triamcinolone acetonide
-
Roth DB, Realini T, Feuer WJ, et al: Short-term complications of intravitreal injection of triamcinolone acetonide. Retina 2008;28: 66-70.
-
(2008)
Retina
, vol.28
, pp. 66-70
-
-
Roth, D.B.1
Realini, T.2
Feuer, W.J.3
-
79
-
-
26944488400
-
Sterile endophthalmitis following intravitreal injection of triamcinolone acetonide
-
Wang LC, Yang CM: Sterile endophthalmitis following intravitreal injection of triamcinolone acetonide. Ocul Immunol Inflamm 2005;13:295-300.
-
(2005)
Ocul Immunol Inflamm
, vol.13
, pp. 295-300
-
-
Wang, L.C.1
Yang, C.M.2
-
80
-
-
19944432858
-
Presumed sterile endophthalmitis following intravitreal triamcinolone acetonide injection
-
Moshfeghi DM, Kaiser PK, Bakri SJ, et al: Presumed sterile endophthalmitis following intravitreal triamcinolone acetonide injection. Ophthalmic Surg Lasers Imaging 2005; 36:24-29.
-
(2005)
Ophthalmic Surg Lasers Imaging
, vol.36
, pp. 24-29
-
-
Moshfeghi, D.M.1
Kaiser, P.K.2
Bakri, S.J.3
-
81
-
-
34548336565
-
Effects of intravitreal triamcinolone acetonide injection with and without preservative
-
Maia M, Farah ME, Belfort RN, et al: Effects of intravitreal triamcinolone acetonide injection with and without preservative. Br J Ophthalmol 2007;91:1122-1124.
-
(2007)
Br J Ophthalmol
, vol.91
, pp. 1122-1124
-
-
Maia, M.1
Farah, M.E.2
Belfort, R.N.3
-
82
-
-
0019192332
-
The efficacy of intraarticular steroids in osteoarthritis: A double-blind study
-
Friedman DM, Moore ME: The efficacy of intraarticular steroids in osteoarthritis: a double-blind study. J Rheumatol 1980; 7: 850-856.
-
(1980)
J Rheumatol
, vol.7
, pp. 850-856
-
-
Friedman, D.M.1
Moore, M.E.2
-
83
-
-
0000545881
-
Inflammatory reaction after intrasynovial injection of micro-crystalline adrenocorticosteroid esters
-
McCarty DJ Jr, Hogan JM: Inflammatory reaction after intrasynovial injection of micro-crystalline adrenocorticosteroid esters. Arthritis Rheum 1964;7:359-367.
-
(1964)
Arthritis Rheum
, vol.7
, pp. 359-367
-
-
McCarty Jr, D.J.1
Hogan, J.M.2
-
84
-
-
50249149459
-
A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema
-
Diabetic Retinopathy Clinical Research Network
-
Diabetic Retinopathy Clinical Research Network: A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008; 115:1445-1446.
-
(2008)
Ophthalmology
, vol.115
, pp. 1445-1446
-
-
-
87
-
-
67349100827
-
-
Kuppermann BD, Williams GA, Blumenkranz MS, et al: Efficacy and safety of a novel intravitreous dexamethasone drug delivery system after applicator or incisional placement in patients with macular edema. Invest Ophthalmol Vis Sci 2006;47:E-ab-stract 5908.
-
Kuppermann BD, Williams GA, Blumenkranz MS, et al: Efficacy and safety of a novel intravitreous dexamethasone drug delivery system after applicator or incisional placement in patients with macular edema. Invest Ophthalmol Vis Sci 2006;47:E-ab-stract 5908.
-
-
-
-
88
-
-
33646925637
-
Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: Thirty-four-week results of a multicenter randomized clinical study
-
Jaffe GJ, Martin D, Callanan D, Pearson PA, Levy B, Comstock T: Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 2006;113:1020-1027.
-
(2006)
Ophthalmology
, vol.113
, pp. 1020-1027
-
-
Jaffe, G.J.1
Martin, D.2
Callanan, D.3
Pearson, P.A.4
Levy, B.5
Comstock, T.6
-
89
-
-
0033761752
-
Fluocinolone acetonide sustained drug delivery device to treat severe uveitis
-
Jaffe GJ, Ben-Nun J, Guo H, Dunn JP, Ashton P: Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmology 2000; 107:2024-2033.
-
(2000)
Ophthalmology
, vol.107
, pp. 2024-2033
-
-
Jaffe, G.J.1
Ben-Nun, J.2
Guo, H.3
Dunn, J.P.4
Ashton, P.5
-
90
-
-
67349168324
-
-
Pearson PA, Levy B, Comstock T; Fluocinolone Acetonide Implant Study Group: Fluocinolone acetonide intravitreal implant to treat diabetic macular edema: 3-year results of a multicenter clinical trial (abstract). Invest Ophthalmol Vis Sci 2006;47:E-abstract 5442.
-
Pearson PA, Levy B, Comstock T; Fluocinolone Acetonide Implant Study Group: Fluocinolone acetonide intravitreal implant to treat diabetic macular edema: 3-year results of a multicenter clinical trial (abstract). Invest Ophthalmol Vis Sci 2006;47:E-abstract 5442.
-
-
-
-
91
-
-
34047216320
-
Retisert: Is the new advance in treatment of uveitis a good one?
-
Mohammad DA, Sweet BV, Elner SG: Retisert: is the new advance in treatment of uveitis a good one? Ann Pharmacother 2007; 41:449-454.
-
(2007)
Ann Pharmacother
, vol.41
, pp. 449-454
-
-
Mohammad, D.A.1
Sweet, B.V.2
Elner, S.G.3
-
92
-
-
54249140002
-
Medidur Insert Technology
-
Mruthyunjaya P, Jaffe GJ: Medidur Insert Technology. Retinal Physician 2007 http://www.retinalphysician.com/article.aspx? article=100862.
-
(2007)
Retinal Physician
-
-
Mruthyunjaya, P.1
Jaffe, G.J.2
-
93
-
-
67349094185
-
-
www.surmodics.com.
-
-
-
-
94
-
-
67349095204
-
-
Dugel PU, Cantrill HL, Eliott D, Mahmoud T, Avery R, Varner SE: Clinical safety and preliminary efficacy of an intravitreal triamcinolone implant (I-vation™ TA) in DME. Invest Ophthalmol Vis Sci 2007;48:E-ab-stract 1413.
-
Dugel PU, Cantrill HL, Eliott D, Mahmoud T, Avery R, Varner SE: Clinical safety and preliminary efficacy of an intravitreal triamcinolone implant (I-vation™ TA) in DME. Invest Ophthalmol Vis Sci 2007;48:E-ab-stract 1413.
-
-
-
-
95
-
-
67349193904
-
-
http://phx.corporateir.net/phoenix.zhtml?c=80353&p= irol-newsArticle&ID=1185643&highlight=.
-
http://phx.corporateir.net/phoenix.zhtml?c=80353&p= irol-newsArticle&ID=1185643&highlight=.
-
-
-
-
96
-
-
33645095226
-
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease
-
Ng EWM, Shima DT, Calias P, Cunningham ET Jr, Guyer DR, Adamis AP: Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 2006;5: 123-132.
-
(2006)
Nat Rev Drug Discov
, vol.5
, pp. 123-132
-
-
Ng, E.W.M.1
Shima, D.T.2
Calias, P.3
Cunningham Jr, E.T.4
Guyer, D.R.5
Adamis, A.P.6
-
97
-
-
25844513658
-
A phase II randomized double-masked trial of pegaptanib, an anti-vascular endo-thelial growth factor aptamer, for diabetic macular edema
-
Cunningham ET Jr, Adamis AP, Altaweel M, et al: A phase II randomized double-masked trial of pegaptanib, an anti-vascular endo-thelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005;112: 1747-1757.
-
(2005)
Ophthalmology
, vol.112
, pp. 1747-1757
-
-
Cunningham Jr, E.T.1
Adamis, A.P.2
Altaweel, M.3
-
98
-
-
33845191304
-
Vascular endothelial growth factor is a critical stimulus for diabetic macular edema
-
Nguyen QD, Tatlipinar S, Shah SM, et al: Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol 2006; 142:961-969.
-
(2006)
Am J Ophthalmol
, vol.142
, pp. 961-969
-
-
Nguyen, Q.D.1
Tatlipinar, S.2
Shah, S.M.3
-
99
-
-
34748876124
-
A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema
-
Scott IU, Edwards AR, Beck RW, et al: A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007; 114:1860-1867.
-
(2007)
Ophthalmology
, vol.114
, pp. 1860-1867
-
-
Scott, I.U.1
Edwards, A.R.2
Beck, R.W.3
-
100
-
-
28444434771
-
Regulatory aspects of drug approval for macular degeneration
-
Gryziewicz L: Regulatory aspects of drug approval for macular degeneration. Adv Drug Deliv Rev 2005;57:2092-2098.
-
(2005)
Adv Drug Deliv Rev
, vol.57
, pp. 2092-2098
-
-
Gryziewicz, L.1
-
101
-
-
38449100932
-
Anti-vascular endothelial growth factor therapy for ocular neovascular disease
-
Andreoli CM, Miller JW: Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Curr Opin Ophthalmol 2007;18:502-508.
-
(2007)
Curr Opin Ophthalmol
, vol.18
, pp. 502-508
-
-
Andreoli, C.M.1
Miller, J.W.2
-
102
-
-
34247562266
-
Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration
-
Chakravarthy U, Adamis AP, Cunningham ET Jr, et al: Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 2006; 113: 1508-1525.
-
(2006)
Ophthalmology
, vol.113
, pp. 1508-1525
-
-
Chakravarthy, U.1
Adamis, A.P.2
Cunningham Jr, E.T.3
-
103
-
-
33745782355
-
Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration
-
Rich RM, Rosenfeld PJ, Puliafito CA, et al: Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006;26:495-511.
-
(2006)
Retina
, vol.26
, pp. 495-511
-
-
Rich, R.M.1
Rosenfeld, P.J.2
Puliafito, C.A.3
-
104
-
-
33845750072
-
Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration
-
Yoganathan P, Deramo VA, Lai JC, Tibrewala RK, Fastenberg DM: Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration. Retina 2006;26:994-998.
-
(2006)
Retina
, vol.26
, pp. 994-998
-
-
Yoganathan, P.1
Deramo, V.A.2
Lai, J.C.3
Tibrewala, R.K.4
Fastenberg, D.M.5
-
105
-
-
0032864292
-
Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 1251-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration
-
Mordenti J, Cuthbertson RA, Ferrara N, et al: Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 1251-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 1999; 27:536-544.
-
(1999)
Toxicol Pathol
, vol.27
, pp. 536-544
-
-
Mordenti, J.1
Cuthbertson, R.A.2
Ferrara, N.3
-
106
-
-
34047175559
-
Targeting VEGF-A to treat cancer and age-related macular degeneration
-
Ferrara N, Mass RD, Campa C, Kim R: Targeting VEGF-A to treat cancer and age-related macular degeneration. Annu Rev Med 2007;58:491-504.
-
(2007)
Annu Rev Med
, vol.58
, pp. 491-504
-
-
Ferrara, N.1
Mass, R.D.2
Campa, C.3
Kim, R.4
-
107
-
-
36549039554
-
Pharmacokinetics of intravitreal ranibizumab (Lucentis)
-
Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ: Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007;114:2179-2182.
-
(2007)
Ophthalmology
, vol.114
, pp. 2179-2182
-
-
Bakri, S.J.1
Snyder, M.R.2
Reid, J.M.3
Pulido, J.S.4
Ezzat, M.K.5
Singh, R.J.6
-
108
-
-
34247400587
-
Pharmacokinetics of intravitreal bevacizumab (Avastin)
-
Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ: Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007;114:855-859.
-
(2007)
Ophthalmology
, vol.114
, pp. 855-859
-
-
Bakri, S.J.1
Snyder, M.R.2
Reid, J.M.3
Pulido, J.S.4
Singh, R.J.5
-
109
-
-
34447634120
-
Treatment of exudative age-related macular degeneration: Many factors to consider
-
Olsen TW: Treatment of exudative age-related macular degeneration: many factors to consider. Am J Ophthalmol 2007; 144: 281-283.
-
(2007)
Am J Ophthalmol
, vol.144
, pp. 281-283
-
-
Olsen, T.W.1
-
111
-
-
0037251511
-
Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co- glycolic)acid microspheres
-
Carrasquillo KG, Ricker JA, Rigas IK, Miller JW, Gragoudas ES, Adamis AP: Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co- glycolic)acid microspheres. Invest Ophthalmol Vis Sci 2003;44:290-299.
-
(2003)
Invest Ophthalmol Vis Sci
, vol.44
, pp. 290-299
-
-
Carrasquillo, K.G.1
Ricker, J.A.2
Rigas, I.K.3
Miller, J.W.4
Gragoudas, E.S.5
Adamis, A.P.6
-
112
-
-
67349256009
-
-
Bethke W: Present and future retinal implants. Rev Ophthalmol 2006; 13.http://www.revophth.com/index.asp?page=1-990.htm.
-
Bethke W: Present and future retinal implants. Rev Ophthalmol 2006; 13.http://www.revophth.com/index.asp?page=1-990.htm.
-
-
-
|